[go: up one dir, main page]

PE20080661A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa

Info

Publication number
PE20080661A1
PE20080661A1 PE2007001213A PE2007001213A PE20080661A1 PE 20080661 A1 PE20080661 A1 PE 20080661A1 PE 2007001213 A PE2007001213 A PE 2007001213A PE 2007001213 A PE2007001213 A PE 2007001213A PE 20080661 A1 PE20080661 A1 PE 20080661A1
Authority
PE
Peru
Prior art keywords
composition
inhibitor
factor
pharmaceutical composition
weight
Prior art date
Application number
PE2007001213A
Other languages
English (en)
Inventor
Omar Abdelfattah Abu-Baker
Jong Hu
Kimberly Anne Lamey
Robert Francis Leposki
Rennan Pan
Kamlesh Rameshchandra Patel
Rahul Parashar Shukla
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080661A1 publication Critical patent/PE20080661A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION MODIFICADA QUE COMPRENDE MINI-COMPRIMIDOS CONTENIDOS EN UNA CAPSULA DE GELATINA DE UN DIAMETRO MENOR A 5MM QUE CONTIENEN: A) UN INHIBIDOR DEL FACTOR Xa TAL COMO (E)-2-(5-CLOROTIEN-2-IL)-N-{(3S)-1-[(1S)-1-METIL-2-MORFOLIN-4-IL-2-OXOETIL]-2-OXOPIRROLIDIN-3-IL}ETENOSULFONAMIDA, DENTRO DE UNA MATRIZ DE UNO O MAS POLIMEROS DE ALTO PESO MOLECULAR TAL COMO HIDROXIMETILCELULOSA QUE SE ENCUENTRA EN UNA CANTIDAD DE 20% A 60% EN PESO DE LA COMPOSICION; B) UN RECUBRIMIENTO ENTERICO TAL COMO COPOLIMERO DE ACIDO METACRILICO; C) CELULOSA MICROCRISTALINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 20% A 50% EN PESO DE LA COMPOSICION. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE TROMBOEMBOLIA, TROMBOSIS, REESTENOSIS
PE2007001213A 2006-09-12 2007-09-10 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa PE20080661A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
PE20080661A1 true PE20080661A1 (es) 2008-06-12

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001213A PE20080661A1 (es) 2006-09-12 2007-09-10 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa

Country Status (16)

Country Link
US (1) US20090285887A1 (es)
EP (1) EP2061439A1 (es)
JP (1) JP2010502762A (es)
KR (1) KR20090052346A (es)
CN (1) CN101516355A (es)
AR (1) AR062721A1 (es)
AU (1) AU2007296311A1 (es)
BR (1) BRPI0716234A2 (es)
CA (1) CA2662542A1 (es)
CL (1) CL2007002618A1 (es)
EA (1) EA200970267A1 (es)
IL (1) IL197295A0 (es)
MX (1) MX2009002669A (es)
PE (1) PE20080661A1 (es)
TW (1) TW200824723A (es)
WO (1) WO2008031782A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002421A2 (en) 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2010226400B2 (en) 2009-03-20 2016-07-14 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US20120189693A1 (en) * 2009-06-25 2012-07-26 Elite Laboratories, Inc. Oral dosage forms
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
CN109602716A (zh) * 2010-02-25 2019-04-12 百时美-施贵宝爱尔兰控股无限责任公司 包含药物组合物的片剂或胶囊剂
EP2608775A2 (en) * 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
PT2627244T (pt) 2010-10-15 2018-10-30 Brain Sentinel Inc Aparelho com sensores de emg para detetar ataques epiléticos
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
IN2015DN01093A (es) 2012-08-28 2015-06-26 Dsm Sinochem Pharm Nl Bv
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
US20190046449A1 (en) * 2016-02-25 2019-02-14 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363123C (en) * 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
AU3240900A (en) * 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Also Published As

Publication number Publication date
BRPI0716234A2 (pt) 2013-10-15
CL2007002618A1 (es) 2008-03-14
MX2009002669A (es) 2009-03-24
AU2007296311A1 (en) 2008-03-20
JP2010502762A (ja) 2010-01-28
WO2008031782A1 (en) 2008-03-20
TW200824723A (en) 2008-06-16
US20090285887A1 (en) 2009-11-19
AR062721A1 (es) 2008-11-26
CN101516355A (zh) 2009-08-26
KR20090052346A (ko) 2009-05-25
EA200970267A1 (ru) 2009-08-28
IL197295A0 (en) 2009-12-24
EP2061439A1 (en) 2009-05-27
CA2662542A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PE20080661A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa
ES2529681T3 (es) Polímeros de colorante
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
BR112013025519A2 (pt) composição farmacêutica
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
NI201100143A (es) Composición farmacéutica sólida que comprende amlodipina y losartan.
UA103844C2 (ru) Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
SV2011003855A (es) Heteroarilos sustituidos
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CR20120296A (es) Nuevos compuestos de espiropiperidina
EA200802324A1 (ru) Новая форма введения рацекадотрила
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CL2007000781A1 (es) Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis
CR20110209A (es) Composición farmacéutica sólida
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
AR048332A1 (es) Formulaciones de tableta recubierta y metodo
EA201070918A1 (ru) Применение ранолазина для лечения сердечно-сосудистых заболеваний
EA201071309A1 (ru) Твердая фармацевтическая композиция
TR201820411T4 (tr) Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.

Legal Events

Date Code Title Description
FD Application declared void or lapsed